Stocks of the Hour: QX Resources, Chimeric Therapeutics, Alliance Nickel
Stocks of the Hour: QX Resources, Chimeric Therapeutics, Alliance Nickel
To register for Friday's webinar click here.
要注册参加周五的网络研讨会，请单击此处。
QX Resources (ASX:QXR) announced that numerous brine aquifers were successfully intersected in the second hole of a two-hole diamond drill (DD) program over the large scale Liberty Lithium brine project in California, USA. The results and interpretations from drillhole 1 are expected in mid-February, with drillhole 2 results in late March. Shares are trading 16.67 per cent higher at 2.1 cents.
QX Resources（澳大利亚证券交易所股票代码：QXR）宣布，在美国加利福尼亚州的大规模Liberty Lithium盐水项目的两孔金刚石钻探（DD）项目的第二洞中，成功穿透了许多盐水含水层。1号钻孔的结果和解释预计将在2月中旬公布，2号钻孔的结果将在3月下旬公布。股价上涨16.67％，至2.1美分。
Chimeric Therapeutics (ASX:CHM), an Australian leader in cell therapy, announced that the first patient in the ADVENT-AML Phase 1B clinical trial in Acute Myeloid Leukaemia (AML) has received treatment with CHM 0201. The trial, now open to enrolment at The University of Texas MD Anderson Cancer Center, will recruit up to 20 patients with newly diagnosed AML. Shares are trading 16 per cent higher at 2.9 cents.
澳大利亚细胞疗法领域的领导者Chimeric Therapeutics（澳大利亚证券交易所股票代码：CHM）宣布，ADVENT-AML急性髓系白血病（AML）1B期临床试验的第一位患者已经接受了CHM 0201的治疗。该试验现已向德克萨斯大学医学博士安德森癌症中心开放报名，将招募多达20名新诊断的急性髓细胞白血病患者。股价上涨16％，至2.9美分。
Alliance Nickel (ASX:AXN) has signed a non-binding term sheet with Samsung SDI for the future offtake of battery grade nickel and cobalt sulphate products from the NiWest Nickel-Cobalt Project in Western Australia. Samsung SDI and Alliance will discuss a potential acquisition by Samsung SDI of an equity interest in the NiWest Project. Shares are trading 56.67 per cent higher at 4.7 cents.
Alliance Nickel（澳大利亚证券交易所股票代码：AXN）已与三星SDI签署了一份不具约束力的条款表，内容涉及未来从西澳大利亚NiWest镍钴项目中收购电池级镍和硫酸钴产品。三星SDI和Alliance将讨论三星SDI可能收购NiWest项目的股权。股价上涨56.67％，至4.7美分。
